Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
28/10/2022
ESGO – 2022 |Efficacy and safety of VB10.16, therapeutic DNA vaccine specifically targeting antigen presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis
05/10/2022
Vaccines Summit – 2022 | Poster: P-005 | Antigen presenting cell targeted T cell DNA vaccine candidate inducing strong and specific cellular responses across multiple T cell epitopes of SARS-COV-2
22/09/2022
A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase 1/2a trial
01/07/2022
Keystone Symposium: Viral Immunity: Basic Mechanisms and Therapeutic Applications | Poster #: 1040 | A DNA COVID-19 vaccine candidate targeting antigen-presenting cell and adapted to RBD of emerging SARS-CoV-2 variants induced strong cross-neutralizing antibodies and protective immune responses in mice
21/04/2022
World Vaccine Congress | Using the Vaccibody™ platform to create new second and third generation vaccines against COVID
Pages:
1
2
3
4
5
6
7
8
9
10
11
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
